THERAPY DOSSIER · th-7604b963cc79

MMS350, a water-soluble oxetanyl sulfoxide

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23606683 ↗2013Reported benefit

Effects of thoracic irradiation on pulmonary endothelial compared to alveolar type-II cells in fibrosis-prone C57BL/6NTac mice.

MouseRadiationC57BL/6NTac

Model: Thoracic irradiation causing late pulmonary fibrosis

RNA and micro-RNA expression correlated with fibrosis, and MMS350 reduced pro-fibrotic gene expression in both pulmonary endothelial and alveolar type-II cells of irradiated mice; conditioned medium from irradiated cells did not alter cell motility in vitro.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…